恒瑞醫藥(600276.SH):簽署SHR7280項目授權許可協議
格隆匯4月7日丨恒瑞醫藥(600276.SH)公佈,公司與MerckKGaA,Darmstadt,Germany公司(簡稱“MerckKGaA”)達成協議,將SHR7280口服GnRH受體拮抗劑項目有償許可給MerckKGaA。SHR7280作為恒瑞自主研發的新型口服小分子非肽類GnRH受體拮抗劑,具有給藥便捷、患者依從性高等特點,有望成為輔助生殖領域全球首個獲批的口服GnRH受體拮抗劑。2023年下半年,該產品啟動應用輔助生殖技術治療的女性受試者中口服SHR7280片在控制性超促排卵(COH)過程中的有效性、安全性及耐受性的多中心、陽性藥物對照的雙盲研究(SHR7280-302研究),並於2024年年底完成臨牀試驗的主要研究部分,並將繼續跟進新生兒的研究終點。MerckKGaA將向恒瑞支付1500萬歐元的首付款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.